• Explore /
  • Poster
  • / Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

Abstract Video & Slides Poster

Authors

Thomas Martin

Thomas G. Martin

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Thomas G. Martin , Amrita Y. Krishnan , Kwee Yong , Katja Weisel , Maneesha Mehra , Sandhya Nair , Keqin Qi , Anil Londhe , Joris Diels , Concetta Crivera , Carolyn Chang Jackson , Yunsi Olyslager , Martin Vogel , Jordan Mark Schecter , Arnob Banerjee , Satish Valluri , Saad Zafar Usmani , Jesus G. Berdeja , Sundar Jagannath

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03548207

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8045)

DOI

10.1200/JCO.2021.39.15_suppl.8045

Abstract #

8045

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Nimer Alsaid

First Author: Anupama Deepa Kumar

First Author: Andrew J Yee

First Author: Pieter Sonneveld